Market cap
₹30,048 Cr
Recently Viewed
Clear AllNSE: MEDANTA | BSE: 543654
₹1,117.25
₹-25.70
(-2.25%)
As on 30-Apr-2026IST
Market cap
₹30,048 Cr
Revenue (TTM)
₹4,182 Cr
P/E Ratio
58.5
P/B Ratio
7.9
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹514 Cr
ROE
15.3 %
ROCE
20.5 %
Industry P/E
46.32
EV/EBITDA
29.8
Debt to Equity
0.1
Book Value
₹141.7
EPS
₹20.6
Face value
2
Shares outstanding
268,851,882
CFO
₹2,788.61 Cr
EBITDA
₹3,843.43 Cr
Net Profit
₹1,861.55 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Global Health
| -5.8 | 13.4 | 8.0 | -5.1 | 29.4 | -- | -- |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Global Health
| 7.8 | 13.4 | 104.6 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Global Health
|
1,117.3 | 30,048.2 | 4,182.4 | 513.8 | 16.6 | 15.6 | 58.5 | 7.9 |
| 1,367.2 | 22,934.5 | 2,762.9 | 509.8 | 22.5 | 21.5 | 45.4 | 9.1 | |
| 666.7 | 26,651.3 | 3,626.9 | 315.0 | 15.0 | 13.3 | 88.6 | 11.5 | |
| 588.8 | 1,909.5 | 766.3 | 80.5 | 15.7 | 8.9 | 23.8 | 2.0 | |
| 254.5 | 343.6 | 166.7 | 7.2 | 3.9 | 3.9 | 36.5 | 1.3 | |
| 476.5 | 9,884.4 | 1,566.5 | 169.5 | 14.8 | 12.7 | 58.7 | 6.6 | |
| 281.8 | 883.9 | 1,231.3 | 29.1 | -4.7 | 4 | 34 | 1.3 | |
| 284.0 | 1,476.2 | 294.1 | 32.4 | 17.4 | 15.1 | 44.3 | 6.2 | |
| 400.3 | 6,375.4 | 792.3 | 135.5 | 23.5 | 26.4 | 46.3 | 9.5 | |
| 1,129.6 | 10,897.0 | 768.1 | 159.9 | 29.2 | 19.3 | 68.3 | 12.0 |
Global Health IPO: Information analysis
2 min read•By Udhayaprakash
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal... disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India. Read more
Incorporated
2004
Chairman
Naresh Trehan
Managing Director
Naresh Trehan
Headquarters
New Delhi, Delhi
Website
Looking for more details about Global Health Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Global Health Ltd is ₹1,117.25 (NSE) and ₹1,117.65 (BSE) as of 30-Apr-2026 IST. Global Health Ltd has given a return of 29.37% in the last 3 years.
The P/E ratio of Global Health Ltd is 58.47 times as on 30-Apr-2026, a 26 premium to its peers’ median range of 46.32 times.
The P/B ratio of Global Health Ltd is 7.89 times as on 30-Apr-2026, a 0 premium to its peers’ median range of 7.89 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
66.85
|
9.50
|
|
2024
|
74.33
|
12.25
|
|
2023
|
43.28
|
5.82
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Global Health Ltd are Rs 1,456.50 and Rs 956.00 as of 02-May-2026.
Global Health Ltd has a market capitalisation of ₹ 30,048 Cr as on 30-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Global Health Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.